Which peptides can legally be compounded?

There is no permanent roster of peptides that are legal to compound and another roster that is not. As a general matter, the federal framework attaches eligibility to the substance and its documentation — whether it corresponds to an approved drug, whether it has a recognized compendial monograph, or whether it appears on a published list of bulk drug substances a compounder may use — rather than to the word peptide. Some peptides sit inside one of those pathways, many do not, and the picture moves as nominations are evaluated and lists are updated. For a wholesale buyer, the practical answer is blunt: compounding eligibility is a question for a licensed compounding pharmacy, your state board of pharmacy, and your attorney — and it is a completely separate question from what a research-use-only supplier such as Real Peptides can sell into your business.

This article is informational and is not legal advice. Nothing below tells you what your operation may or may not do; it tells you which questions to put in front of counsel so you get a usable answer.

Compounding is a permission, not a product category

The first mistake operators make is treating compoundable as a property of a molecule, like solubility. It is closer to a permission slip issued to a specific licensed entity, for a specific purpose, using a specific grade of input material with a specific paper trail behind it.

The federal provisions commonly referred to as 503A and 503B of the Federal Food, Drug, and Cosmetic Act describe two different categories of compounder — traditional pharmacy compounding on one hand, registered outsourcing facilities on the other — each with its own conditions. Neither of those provisions is a shopping list. They are conditions that a compounder must satisfy, and the conditions run to the sourcing of the active substance, the qualification of the supplier, the facility's own registration status, and the intended scope of the preparation.

That matters for a med spa owner, clinic operator, telehealth founder, or reseller for one reason: none of those permissions transfer to you by buying inventory. A supplier cannot confer compounding eligibility on a business, and no certificate a supplier issues changes the licensure status of the buyer. If a vendor implies otherwise, treat it as a signal about the vendor.

The doors a substance has to walk through

When counsel or a compounding pharmacist evaluates a specific substance, the analysis usually reduces to a small number of doors. The substance either fits through one of them with documentation, or the conversation ends. The table below is a map of the questions, not a determination about any particular compound.

Several peptides have been evaluated through these mechanisms and the outcomes have not been uniform. Rather than repeat any status here — which would be stale the moment a list is revised — read the current published documents yourself, note the revision date on the page you read, and have counsel confirm the reading before you build anything around it. A supplier's summary of a regulatory status, including any summary in an article like this one, is not a substitute for the primary document.

Why the answer keeps moving, and how to check it without guessing

Substances enter this process by nomination, get evaluated, and are placed into categories that reflect where that evaluation stands. Categories are revisited. Guidance documents are reissued. Something described as unresolved in one revision can be resolved in the next, in either direction.

This is why an operator should never take a screenshot of a list and file it as settled knowledge. Build a small verification habit instead:

First, always work from the current published source rather than a secondary summary, and record the date you checked it. Second, distinguish between what a document says about the substance and what it says about the compounder — the two constraints stack, and satisfying one does nothing for the other. Third, route the specific question through the people who carry the licence: a compounding pharmacist for practice questions, your state board for scope questions, your attorney for exposure questions. If any part of your operation touches animal health, that is a separate regulatory lane again, and the person to ask is your veterinarian alongside your attorney — not a supplier's sales rep.

And fourth, be skeptical of certainty. Anyone who answers a compounding-eligibility question instantly, for every compound, without asking what kind of entity you are, is not answering the question you asked.

Research-grade material and compounding inputs are different supply chains

This is the distinction most likely to save an operator from an expensive misunderstanding, so it is worth stating plainly.

Research-use-only peptides are sold for laboratory and research applications. They are not FDA-approved drugs, they are not sold for human or animal consumption, and they are not offered as active pharmaceutical ingredients for compounding. The documentation that accompanies research material — identity, purity, contaminant screening — answers scientific questions about what is in the vial. It does not answer regulatory questions about what a licensed compounder may lawfully do with a substance, because those are different questions with different evidentiary requirements.

A supplier that blurs the two lines is telling you something. If a vendor markets research compounds while gesturing at clinical use, or implies that a certificate of analysis functions as a compounding credential, the compliance posture of that vendor is already loose. Real Peptides operates on the research side of that line and says so consistently: everything in the catalog, from single compounds such as BPC-157 and GHK-Cu through the broader popular peptides collection, is research use only, and the wholesale program is built for businesses stocking research inventory.

Where efficacy comes up at all, keep it honest. Research suggests certain peptide sequences are interesting in specific experimental contexts; studies indicate mechanisms worth investigating. That is the appropriate register for a research catalog, and it is the register a careful buyer should expect from a supplier's marketing too.

What to verify before you choose any supplier

Set the legal question aside for a moment, because supplier diligence is a separate discipline and most buyers underweight it. Four things are worth checking on every vendor you consider.

Analytical evidence you can actually inspect. Ask for a certificate of analysis tied to the batch number on the vial, not a generic sample document. Ask whether purity is established by HPLC and what identity confirmation accompanies it. A COA that cannot be matched to the specific lot in your hands is decoration.

Whether COAs cost extra. Some operations treat lab documentation as a paid add-on or release it only on request. Testing evidence that sits behind a paywall or a sales conversation is a structural problem, not an inconvenience — it means the default state of the product is undocumented.

Pricing you can see before you commit. Hidden wholesale pricing, quote-only tiers, and minimums that materialise late in the process make it impossible to model your own inventory costs. Margins and order economics vary widely with volume, category, and how you run your business, so what you need from a supplier is not a promised number but a transparent structure you can plug into your own math.

Fulfillment you can plan around. Where does the order ship from, what is the realistic window, and who answers when a shipment goes sideways. Reliability compounds; a supplier that is cheap and erratic costs more than a supplier that is predictable.

What Real Peptides does differently

Real Peptides is built around removing the guesswork from those four checks.

Purity is specified at 99%+ by HPLC. Every batch runs through a multi-assay testing panel covering identity, purity, and contaminant screening, and the resulting certificates of analysis are publicly verifiable — a prospective partner can read the lab results before opening an account, without asking permission and without paying for the privilege. That is the point of publishing them: documentation that only appears after a sales conversation is documentation the buyer cannot use to evaluate the seller.

Fulfillment is handled domestically, with orders shipping in five to seven days. Wholesale pricing tiers are structured rather than negotiated case by case in the dark, so a buyer can see how volume affects cost before committing to a first order.

Access runs through a three-step wholesale application: submit business details, get reviewed for qualification, and receive tier pricing and account access. The review step exists because a wholesale account is a business relationship, not a checkout button — the program is designed for med spas, clinics, wellness centers, telehealth companies, and resellers stocking research inventory under their own compliance obligations.

What Real Peptides does not do is equally important. It does not represent research compounds as therapeutics, does not supply material as compounding API, and does not advise buyers on their licensure. Those boundaries are the reason the supplier relationship stays clean.

Where a qualified buyer goes next

If your compounding questions belong with a pharmacist and your licensure questions belong with your board and your attorney, the remaining question — where research inventory comes from, with verifiable analytics behind it and pricing you can model — is the one a supplier can actually answer. Businesses ready to stock research peptides under transparent tiers can start the three-step application and have their account reviewed for qualification.

More detail on tier structure, qualification criteria, and what the review covers is available on the wholesale peptides program page, and businesses ready to begin can apply for a wholesale account directly.